3 active not recruiting, 3 completed, 2 terminated. 5 Phase 2, 2 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 5 | Active not recruiting 2, Completed 2, Terminated 1 |
| Phase 1 | 2 | Completed 1, Terminated 1 |
| Phase 3 | 1 | Active not recruiting 1 |
Follow Melanoma of Unknown Primary: new trials by email Literature Review of Melanoma of Unknown Primary trials Research Report on Melanoma of Unknown Primary
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Stereotactic Radiosurgery and Immune Checkpoint Inhibitors With NovoTTF-200M for the Treatment of Melanoma Brain Metastases Ipilimumab, Nivolumab, Pembrolizumab - Clinical Stage IV Cutaneous Melanoma AJCC v8, Melanoma of Unknown Primary | Phase 1 | Terminated | Emory University | 1 | 2022-10-13 | 2026-04-23 |
| A Study Evaluating Whether Pembrolizumab Alone or in Combination With CMP-001 Improves Efficacy of Treatment in Patients With Operable Melanoma Biopsy Procedure, Biospecimen Collection, Computed Tomography - Clinical Stage III Cutaneous Melanoma AJCC v8, Melanoma of Unknown Primary | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 60 | 2021-10-15 | 2026-09-29 |
| Testing Treatment With Encorafenib and Binimetinib Before Surgery for Melanoma With Lymph Node Involvement Binimetinib, Conventional Surgery, Encorafenib - Melanoma of Unknown Primary, Metastatic Malignant Neoplasm in Lymph Node | Phase 2 | Terminated | ECOG-ACRIN Cancer Research Group | 3 | 2021-09-22 | 2026-10-06 |
| Using Biomarkers to Help Guide Safe Immunotherapy Discontinuation in Patients With Unresectable Stage IIIB-IV Melanoma, The PET-Stop Trial Ipilimumab, Nivolumab, Patient Observation - Advanced Melanoma, Clinical Stage III Cutaneous Melanoma AJCC v8 | Phase 2 | Active not recruiting | ECOG-ACRIN Cancer Research Group | 150 | 2021-02-09 | 2026-09-15 |
| Testing Treatment With Ipilimumab and Nivolumab Compared to Treatment With Ipilimumab Alone in Advanced Melanoma Ipilimumab, Nivolumab - Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8 | Phase 2 | Completed | National Cancer Institute (NCI) | 94 | 2017-10-23 | 2025-01-13 |
| Pembrolizumab and Stereotactic Radiosurgery for Melanoma or Non-Small Cell Lung Cancer Brain Metastases Pembrolizumab, Stereotactic Radiosurgery - Metastatic Malignant Neoplasm in the Brain, Metastatic Melanoma | Phase 1 | Completed | Emory University | 25 | 2016-10-04 | 2026-03-09 |
| A Vaccine (CDX-1401) With or Without a Biologic Drug (CDX-301) for the Treatment of Patients With Stage IIB-IV Melanoma DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Poly ICLC, Recombinant Flt3 Ligand - Cutaneous Melanoma, Melanoma | Phase 2 | Completed | National Cancer Institute (NCI) | 60 | 2014-04-09 | 2021-11-16 |
| Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery Ipilimumab, Quality-of-Life Assessment, Recombinant Interferon Alfa-2b - Melanoma of Unknown Primary, Recurrent Melanoma | Phase 3 | Active not recruiting | National Cancer Institute (NCI) | 1673 | 2011-06-17 | 2026-10-22 |
Melanoma (6) · Uveal Melanoma (3) · Brain Neoplasms (2) · Carcinoma, Non-Small-Cell Lung (1) · Lymphatic Metastasis (1)
Neoplasms (6) · Neoplasms by Histologic Type (6) · Neoplasms by Site (6) · Neoplasms, Germ Cell and Embryonal (6) · Neoplasms, Nerve Tissue (6) · Neuroectodermal Tumors (6) · Neuroendocrine Tumors (6) · Nevi and Melanomas (6) · Skin Diseases (6) · Skin Neoplasms (6) · Skin and Connective Tissue Diseases (6) · Eye Diseases (3) · Eye Neoplasms (3) · Uveal Diseases (3) · Uveal Neoplasms (3)
CTLA-4 Antigen (4) · Ipilimumab (4) · pembrolizumab (4) · Nivolumab (3) · Radiosurgery (2) · Biopsy (1) · Interferon alpha-2 (1) · Introns (1) · Magnetic Resonance Spectroscopy (1) · Observation (1) · Specimen Handling (1) · Surgical Procedures, Operative (1) · Watchful Waiting (1) · alovudine (1) · binimetinib (1)
National Cancer Institute (NCI) (4) · ECOG-ACRIN Cancer Research Group (2) · Emory University (2)
United States (8) · Canada (1)
Ahmad Tarhini (2) · Ari M Vanderwalde (1) · Geoffrey T Gibney (1) · Leslie A Fecher (1) · Mohammad K Khan, MD, PhD (1) · Mohammad K. Khan, MD, PhD (1) · Nina Bhardwaj (1)
PMID 25649350, PMID 35121932, PMID 35659704, PMID 36029412, PMID 37592104
U10CA180820 (4), P30CA138292 (2), P30CA015704 (1), P50CA121973 (1), U01CA154967 (1), U10CA021115 (1), U10CA180888 (1), U24CA196172 (1)